Objective: This study examined adherence, discontinuation, and switching of rheumatoid arthritis (RA) biologics over a 1-year period after initiation of the biologic treatment in Medicaid patients with RA.
Introduction
Rheumatoid arthritis (RA) is a debilitating chronic inflammatory disease of the joints that affects approximately 1% of the population [1] . RA adversely affects daily living and functional status, with 33% of sufferers unable to work 5 years after disease onset. RA also is associated with lifespan reduction of 5 to 10 years [2] .
Biological treatments represent promising advances for individuals with RA, and have been associated with significant improvement in outcomes including reduction in pain, joint swelling, serologic inflammatory indices, and rates of radiologic damage [3] . There has been a rapid growth in the availability of such new treatments for RA, with eight biologic therapies to treat RA approved by the US Food and Drug Administration over the past 10 years [4] [5] [6] [7] [8] [9] [10] [11] . Nevertheless, the potential therapeutic benefits of biologics demonstrated in clinical trials may be undermined by poor adherence and early discontinuation of treatment (i.e., nonpersistence) in clinical practice. In this time of growing demands on limited health-care resources, poor adherence further strains these resources because effectiveness of the incomplete treatment may be low to none whereas the costs incurred for these expensive treatments are high. Hence, nonadherence also raises concerns for payers who are responsible for the high costs of these agents as well as the medical costs ensuing from the progression of disease and need for more aggressive treatment due to nonadherence. Therefore, an assessment of the adherence to and persistence on RA biologics is essential to understanding the costs and effectiveness of these therapies in the real-world setting.
Few studies have examined adherence to and/or persistence on biologics in RA patients in the United States [12] [13] [14] [15] [16] [17] [18] . This is particularly surprising given the first availability of these biologics on the US market over a decade ago and wide accessibility to insurance claims databases permitting relatively quick and inexpensive analyses of medication use patterns in large populations. Furthermore, a majority of these studies have focused on patients from large US private health plans or managed care organizations which generally exclude poorer, sicker, disabled, or older patients covered under the Medicaid or Medicare programs. Only one study to date has examined biologic use in Medicaid patients with RA [13] . Nevertheless, the data in this study were limited to the single state of Tennessee and hence its results may not generalize to Medicaid enrollees in other states. Because the Medicaid population comprises a large part of our public payer health system as well as tends to be underrepresented in clinical trials, it is important to examine adherence to and discontinuation of RA biologics in such patients.
This study used administrative claims data from three large state Medicaid programs to examine adherence, discontinuation, and switching of RA biologics over a 1-year period after initiation of the biologic treatment in Medicaid patients with RA.
Methods

Data Source
We used data from the Medicaid Analytic Extract (MAX) files for the states of California (CA), Florida (FL), and New York (NY). MAX files are state Medicaid research files containing beneficiary-level enrollment, diagnoses, and medical and prescription utilization and expenditure data on a calendar year basis. MAX files include one file with annual enrollment information and four claim files (inpatient, other therapy, long-term care, prescription drugs). Because Medicare is the primary payer for dual eligibles (i.e., elderly and with disability patients with Medicaid and Medicare coverage), Medicare Parts A and B claims data were linked to the MAX files for the dual eligibles to supplement their health-care services captured in the MAX files. Medicare-linked MAX files were obtained from 1999 to 2003 (the latest available data at the time of the analysis).
Study Sample
The study sample consisted of noninstitutionalized fee-for-service Medicaid patients with RA who had newly initiated a biological agent between January 1, 2000 and December 31, 2002. During this period, the two biologics that were approved and widely used were infliximab and etanercept. Anakinra was also available during this time frame, although less frequently used. Hence, the sample included patients newly initiating one of these three biologics. These biologics were covered under all three state Medicaid programs, with minimal copayments ranging from $0 (FL) to $2 (NY). Only CA required prior authorization for these biologics; however, the requirement was waived if the biologic was administered in the physician's office.
The date of the first medical or prescription claim indicating use of a biological between January 1, 2000 and December 31, 2002 was denoted as the index date. Patients were required to have continuous eligibility under fee-for-service Medicaid in the 12-month preindex and 12-month postindex dates. A biological agent was considered newly initiated (i.e., the "index biologic") based on the absence of previous use of any RA biologic in the 12-month preindex date. Patients were required to have at least one inpatient or two outpatient diagnoses of RA (International Classification of Diseases-9-Clinical Modification codes 714.xx) across Medicaid or Medicare claims in the 12-month preindex date. The 12-month period postindex date was treated as the follow-up period over which outcomes of adherence and discontinuation to the index biologic drug were estimated.
Adherence
Adherence was defined using the proportion of days covered (PDC), measured as the number of days covered with biologic divided by the fixed time interval of 365 days from date of index biologic therapy initiation (i.e., 12-month postindex) [19] .
Etanercept and anakinra were subcutaneous self-injectable biologics taken twice weekly (25 mg) and daily (100 mg), respectively. These were dispensed via the pharmacy and hence identified from the prescription claims using National Drug Codes. The "days supply" field available on these claims was used to identify covered days. These comprised the time between the date of prescription fill and the end date of the prescription (i.e., the fill date plus the days' supply of the prescription). Only if a refill for the same biologic occurred before the end date of the previous prescription and the number of overlap days was equal to or fewer than the number of days permitted under the state Medicaid program-specific early refill policies (i.e., refills permitted only 2 days before previous prescription expires in FL and only after 75% of the previous prescription is used for CA and NY [e.g., 7 days for a 28-day prescription]), the days' supply for the new prescription was appended to the end date of the previous prescription. If the end date of the last prescription fill ran past the last day of the 12-month follow-up period, then it was truncated at the last date of the follow-up period.
Infliximab is a biologic requiring intravenous infusion usually for up to 4 hours in a physician's clinic or outpatient hospital setting, and hence identified from the medical claims using the Healthcare Common Procedure Coding System code J1745. Unlike the prescription claims for etanercept and anakinra, there is no "days supply" data field associated with intravenous administrations of infliximab recorded in the medical claims. Therefore, to calculate the PDC measures for infliximab, we had to "assign" days supply for each infliximab administration. We assigned days supply based on infliximab's recommended dosing schedule and individual dosing patterns identified for each patient in the data (Table A1 at: http://www.ispor.org/ Publications/value/ViHsupplementary/ViH13i6_Li-Doshi.asp). Unlike the pharmacy-dispensed self-injectables in which an overlap (at a maximum of 7 days) because of an earlier refill would result in the days' supply being appended at the end of the previous prescription, we did not append the days' supply for an infliximab administration received earlier than the dosing schedule (e.g., at week 5.5 instead of week 6) to the expected end date of the previous administration. Instead, the end date of the previous administration was truncated to the start date of the next administration. This was because an earlier infusion of infliximab is not the same as an earlier refill of self-injectables, wherein the previous stock of syringes would be first exhausted before the new refill syringes are started to be used by the patients.
We examined PDC for all three index biologic medications in subgroups of patients without any diagnosis of specific types of cancers and/or infections that might require the biologic to be withheld or discontinued in the postindex period and hence reduce the adherence rates. We also examined PDC in subgroups of patients who may be using these biologic medications in combination with oral disease-modifying antirheumatic drugs (DMARDs) identified as those filling an oral DMARD prescription on or within 30 days of the index biologic initiation date. As part of sensitivity analysis, we extended the 30-day window to 90 days to define combination use with oral DMARDs. Finally, we also explored the subgroup of early-stage RA patients in our sample. Given the lack of clinical measures such as RA disease activity, it is difficult to reliably identify early-stage RA patients in claims data. Nevertheless, we used a proxy by examining a subset of patients who were likely newly diagnosed RA patients in the 12-month preindex period. We identified such patients by limiting our study sample to those who did not have claims-based evidence of any RA diagnosis or oral DMARDs filled in the first 6 months of the 12-month preindex date.
In addition to using a continuous measure of PDC, we also created a binary indicator of whether the patient was adherent or not based on a PDC Ն 0.80, a cutoff commonly used in medication adherence studies including those examining RA biologics [12, 14, 17] . Nevertheless, because this is an arbitrary cut point we also conducted sensitivity analysis using alternative cutoffs of PDC Ն 0.70 and 0.90.
Discontinuation
Although the PDC measures indicate the extent of medication availability in the observed period, it does not indicate whether measures less than 1.0 indicate gaps in use that were dispersed over the time period, or existed for a continuous period, or whether the patient completely discontinued therapy. Each of these scenarios has different clinical implications. Hence, to further understand the RA biologics use, we also measured the outcome of discontinuation generally defined in the literature as a continuous gap of a prespecified length in the use of the biologic. Our primary outcome of discontinuation was a dichotomous measure indicating the incidence of a 90-consecutive-day period without a biologic. Again, such continuous periods were calculated based on the prescription fill date and days' supply for the index biologic prescriptions in the 12-month follow-up period. We also measured the time to discontinuation defined as the time from index date to the beginning date of the first 90-consecutive-day gap. Even though some patients may reinitiate the biologic agent after the first 90-consecutive-day gap, for the purpose of this study they were defined as having discontinued the biologic agent. This definition of discontinuation, based on a defined gap in therapy, has been used in previous studies of RA biological use [13, [15] [16] [17] [18] . Nevertheless, the length of the gap used to define discontinuation of RA biologics has varied in terms of 30 days [16] [17] [18] , 60 days [15] , or 90 days [13] across studies. Hence, we conducted a sensitivity analysis of discontinuation based on continuous gaps of 30, 60, 90, and 120 days.
Switching
We also separately measured whether patients who discontinued the index biologic switched to another biologic. Switching was defined as the first occurrence of a prescription fill or administration of a second (different) biologic medication within 90 days of the last day supply of the index biologic and no evidence of use of the second (switched-to) biologic in the 120 days before discontinuation date of the index biologic. The latter criterion is important to help identify true switches by ensuring that the patient was not already using the second biologic before discontinuing the index biologic. In sensitivity analyses, we used a continuous gap of 120 days to define discontinuation of the index biologic and scanned this 120-day period for the occurrence of a prescription fill or administration of a second (different) biologic medication. Because the self-injectable adalimumab was approved during the follow-up period in our study (i.e., December 2002), we also examined switching to this biologic in addition to infliximab, etanercept, and anakinra.
Other RA Biologic or DMARD Use
We also measured the use of any other biologic during the 12-month postindex date in all patients (regardless of whether they discontinued the index biologic or not and the timing of their switch). We similarly measured use of other oral DMARDs, particularly methotrexate, which is indicated in combination with infliximab during the 12-month period postindex date.
Statistical Analysis
Multivariable analyses were conducted to examine the sociodemographic and clinical factors associated with RA biologic adherence and persistence. Sociodemographic variables included patients' age, sex, race, dual-eligibility status, state, and year of the index date. Because measures of RA serologic status or functional status are not available in claims data we included binary indicators for any hospital admission with RA as the primary diagnosis and history of use of other prescribed RA drug classes (oral DMARDs, steroids, opioids, nonsteroidal antiinflammatory drugs, cyclooxygenase-2 inhibitors, acetaminophen-containing products, salicylate-containing products, and tramadol) in the 12-month preindex period as a marker of RA severity. In addition, we also included the prescription drug hierarchical condition category (RxHCC) risk score measured in the 12-month preindex period as an overall measure of comorbidity and prescription burden, with a higher score indicating a higher burden [20] . This single risk score accounts for the presence of 184 medical conditions based on the diagnoses recorded on beneficiaries' medical claims and has been widely used for adjusting potential confounding in studies of medical and drug use [21] [22] [23] . Finally, all models included dummy variables for the index biologics (etanercept, infliximab, or anakinra). Logistic regression was used for binary outcomes such as percent adherent (i.e., PDC Ն 0.80) and discontinuation. All analyses were conducted in SAS version 9.1.3 (SAS Institute, Cary, NC) and STATA version 9.0 (StataCorp LP, College Station, TX).
Results
Sample Characteristics
A total of 5390 users of etanercept, anakinra, and infliximab with an RA diagnosis were identified between 2000 and 2002. Of these 3072 had continuous eligibility under fee-for-service Medicaid in the 12-month preindex and 12-month postindex dates. After applying additional sample selection criteria, the final sample included 2638 patients with 1359 patients identified in the etanercept group, 267 patients in the anakinra group, and 1012 in the infliximab group (Table 1 ). The mean age of patients was similar in the etanercept (54.9 years) and the anakinra (55.9 years) groups, but was significantly higher in the infliximab group (63.3 years, P < 0.05). About twice as many patients were over the age of 65 in the infliximab group (57%) compared to the etanercept group (29%, P < 0.05), whereas there were no differences between the anakinra and etanercept groups. Nearly 90% of the patients in all three biologic groups were female and around half of the patients were white. The percentage of patients who were dually eligible for Medicaid and Medicare was significantly higher in the infliximab group (96%, P < 0.05) relative to the etanercept group (53%) and anakinra group (58%). Between 8% and 12% of the patients had a cancer diagnosis, and 39% to 49% of the patients had an infection diagnosis across the three groups that may have required RA biologic treatment to be put on hold or discontinued in the 12-month postindex period. Infliximab users were significantly more likely to have these diagnoses relative to etanercept users (P < 0.05), whereas the rates in the anakinra group were similar to the etanercept group. All three groups had high rates of other RA medication use in the 12-month preindex period; whereas the rates of use of different RA drug classes were significantly different across the groups (see Table 1 ). Between 82% and 86% of the patients used an oral DMARD (with 55-64% specifically using methotrexate). Use of systemic corticosteroids (71-78%) and opioids (54-61%) was also high across the groups. The infliximab (1.0) and anakinra (0.89) groups had significantly higher mean RxHCC risk scores than the etanercept group (0.81). Table 2 and Figure 1 present measures of adherence to each of the index biologic medications. A majority of the etanercept (90%) and infliximab (96%) users had more than one fill or administration in the 12-month postindex period; however, 22% of anakinra users had no additional fills after the index biologic during this time frame (data not shown). Hence, over the 12-month follow-up period, anakinra users had the lowest mean PDC (0.36) and the lowest percentage (10.5%) of adherent patients (based on PDC Ն 0.80) across all three groups (P < 0.05). The mean PDC for etanercept users was also low at 0.57, with only about one-third (32%) of etanercept users being coded adherent (based on PDC Ն 0.80). Infliximab users had the highest PDC (0.64); however, only 43% were deemed adherent (based on PDC Ն 0.80). The use of a higher cutoff than 0.80 to define patients as adherent (i.e., PDC Ն 0.90) resulted in a large relative decrease of approximately 40% to 50% across all three biologics whereas decreasing the cutoff (i.e., PDC Ն 0.70) resulted in an absolute increase of only about 4% to 10% in the percent adherence rates for etanercept and infliximab and only 5% for anakinra (Fig. 1) . Table 2 also displays mean PDC measures for all three index biologic medications in subgroups of patients without any diagnosis of a cancer and/or infection that might require the biologic to be withheld or discontinued in the postindex period. The mean PDCs in these subgroups were only slightly higher than those reported in the overall sample. Similarly, the mean PDCs in the subgroups of patients using oral DMARDs on or within 30 days (or 90 days) of the index biologic initiation date were only marginally higher than the overall sample. The mean PDC in the newly diagnosed RA subgroup was slightly lower for both etanercept (0.53) and infliximab (0.58), and slightly higher for anakinra (0.46). Table 3 presents the measures of discontinuation with and switching from the three index biologic medications over a fixed 12-month follow-up period. Anakinra had the highest discontinuation rates (70% with Ն120 days continuous gap and 89% with Ն30 days continuous gap). Etanercept and infliximab had comparable discontinuation rates which were substantially lower than those for anakinra. Nevertheless, about one-third of the users in both groups had a continuous gap of Ն120 days and about two-thirds had a continuous gap of Ն30 days. The mean time to discontinuation among those who discontinued across the three groups ranged between 93 days and 123 days across all measures.
Adherence
Discontinuation
Switching
Among patients who discontinued the index biologic for Ն120 days over a fixed 12-month period, very few newly initiated another biologic over this 120-day period, particularly among discontinuers of etanercept or infliximab. Among discontinuers of anakinra, about 9% switched to etanercept, and 4% each to infliximab and adalimumab. Similar rates of switching were observed among patients who discontinued the index biologic for Ն90 days over a fixed 12-month period.
Other RA Biologic or DMARD Use
An examination of other RA biologic use in the 12-month postindex biologic initiation indicates that very few of the etanercept and infliximab users received other biologic therapies. On the other hand, 21% of the anakinra patients received etanercept, 7% received infliximab, and 16% received adalimumab at some point during the 12-month post-anakinra initiation. Also, a majority of the patients in all three index biologic groups filled at least one oral DMARD prescription within 12-month postindex date (78, 77, and 87% for etanercept, anakinra, and infliximab, respectively). Specifically, a large percentage of patients received methotrexate over this 1-year period (48, 45, and 63% for etanercept, anakinra, and infliximab, respectively). 
Factors Associated with Adherence and Discontinuation
Discussion
This study was a comprehensive evaluation of the adherence, discontinuation, and switching patterns of etanercept, anakinra, and infliximab among Medicaid enrollees with RA. Unlike clinical trial data, this study provides valuable insights on the patterns of use of newly initiated RA biologics in routine clinical practice and allows for the evaluation of biologic adherence and persis- tence among RA patients in three large state Medicaid programs whose combined enrollment represents approximately one-third of the total Medicaid enrollment in the United States [24] . We find that adherence to the individual biologics was low and a substantial proportion of patients on each of the three biologics discontinued their use within 12 months of initiation without switching to other biologics during the course of follow-up over 1 year. The lack of information on reasons for nonadherence in administrative claims data makes it difficult to assess whether patients were interrupting or discontinuing biologic use for clinically appropriate reasons such as incidence of adverse events or lack of treatment response. Hence, we cannot expect an adherence rate of 1.0 in the sample. Nevertheless, we found very similar low rates of adherence (mean PDC: 0.37-0.68) in the sample even after excluding patients who developed infections or cancers after biologic treatment initiation, both potential reasons for interrupting or discontinuing biologic use. Also, if the high discontinuation rates (90-day continuous gap: 41-76%) were due to patients not having a clinical response to the index biologic, then ideally one should have observed concurrent switching to another biologic. Nevertheless, our results indicated little switching to alternatives among the three biologic users. These findings highlight several missed opportunities in maximizing the potential therapeutic benefits of biologics in realworld settings.
In general, our study found lower adherence and higher discontinuation rates for these biologics than those reported in the literature. For instance, studies examining adherence to etanercept over a fixed observation period of 1 year have reported the medication possession ratio (MPR) measure (calculated as the total number of days of medication supplied within a period, divided by the number of days in the period) ranging from 0.65 to 0.83 [12] [13] [14] 17] . Also, the rates of etanercept discontinuation (50% with 30-day gap [18] and 45% with 60-day gap [6] ) were lower than those reported in our study. Similarly, mean adherence to infliximab over 1 year was much higher (MPR: 0.81) [12] and its discontinuation rate much lower (37.8% with 60-day gap) [15] . One explanation for these differences in findings may be that all of these studies in the literature have been conducted in US health plans comprising of privately insured enrollees. Clearly, our study sample of Medicaid enrollees has a much lower socioeconomic status than these commercially insured patients which has also been correlated with poorer adherence [25] . Another explanation for our lower adherence rates is the discordance in the definitions of adherence and discontinuation. For instance, even Grijalva et al., the only previous study of RA biologics using Medicaid data [13] , reported the MPR for etanercept at 0.83 and infliximab at 0.90, which is much higher than our reported PDC measures for these two biologics. This is because as opposed to the MPR measure in this and most other previous studies, our study used the more conservative PDC measure which counts each day in the 12-month observation period as covered with a days' supply of the medication or not (i.e., PDC would strictly be Յ1.0). Because the MPR simply aggregates the total days' supply of all prescriptions filled during the observation period, it generally overestimates adherence because of any overlapping prescriptions resulting from an early fill (i.e., MPR could potentially be >1.0). Furthermore, Grijalva et al. examined adherence by "dividing the aggregated number of days supply obtained during the episode by the length of the episode, excluding the last prescription fill [13] ." Use of the time interval between the first and last prescription fill to define the observation period in the MPR results in an artificial exclusion of the most nonadherent patients (i.e., those who only had one prescription and then discontinued use). Also, patients who used only two or three prescriptions during the year, all of them consecutively without any gaps, would be coded as perfectly adherent. Finally, Grijalva et al. did not describe how they applied their MPR definition to measure adherence to infliximab [13] .
Because it is administered in the physician's office, infliximab claims appear in medical and not prescription claims data, and hence lacks a variable on the days' supply, which is needed to calculate the traditional measures of adherence (e.g., MPR, PDC) and discontinuation for outpatient prescription drugs using prescription claims. In addition to using a more rigorous measure (PDC) for biologic adherence compared to previous studies, our study is also the first to propose a comprehensive method (Table A1 at: http://www.ispor.org/Publications/value/ ViHsupplementary/ViH13i6_Li-Doshi.asp) to develop a parallel measure of adherence to infusion biologics such as infliximab. Our study found that anakinra had the lowest adherence and highest discontinuation rates across all three biologics, followed by etanercept and then infliximab. The poor compliance with anakinra may be because of its daily injection schedule, poor efficacy, and side-effect profile. Two recent systematic reviews have concluded that anakinra was less efficacious, had a higher incidence of injection site reactions, and was more likely to lead to withdrawals due to adverse events compared to other biologics like etanercept [26, 27] . Our finding that infliximab users were more likely to be adherent than etanercept users is also consistent with earlier literature [12] [13] [14] . Although both agents have similar efficacy, issues such as route and frequency of administrations may influence patient treatment preferences and adherence. Some patients, particularly older patients, may tend to prefer infusion biologics like infliximab, given the clinical assistance received in terms of administration by a physician or nurse as opposed to the subcutaneously injected biologics like etanercept that require self-administration and need to be administered more frequently [28, 29] . On the other hand, visiting a physician's office to receive a 4-hour infusion may be less preferable to others given the time and travel costs involved. Unfortunately, administrative claims data do not contain information on such factors and hence further research is needed to better understand why Medicaid patients are more likely to be adherent to infliximab as opposed to etanercept.
Another noteworthy finding of our study was the variations in biologic adherence and discontinuation across state Medicaid programs. Medicaid patients in FL were less likely to be adherent and more likely to discontinue their index biologic as compared to patients in CA even after controlling for demographic and clinical characteristics. State Medicaid prescription policies are unlikely to explain this finding because the FL program charged no copayments and did not subject these biologics to prior authorization or a preferred drug list. This raises the question of whether state-level variation in physician practice patterns or other regional health-care resources contribute to these findings. It is also possible that patient characteristics such as disease activity and radiographic progression which are not captured in claims data are partly responsible for this observed variation across states. Future research should examine state-level variation in the patterns of use of these biologic agents and the potential factors contributing to this variation that are amenable to interventions to improve adherence.
There are some limitations of this study that deserve acknowledgment. First, the study used administrative claims data which are collected for the purpose of payment rather than research. The presence of a claim for a filled prescription for the self-injectable does not indicate that the biologic was actually taken by the patient as prescribed. On the other hand, a claim for an administration of infliximab does indicate, except for the presumably rare case of fraudulent claims filed by providers, that this biologic was indeed taken by the patient given its infusion form. Second, there were differences in baseline characteristics across the three biologic groups. Even though multivariate regressions were used to control for observed differences by adjusting for baseline characteristics, it is likely that unobserved confounders such as RA disease activity and disability also contribute to the difference in adherence and discontinuation across the three index biologics. Third, we were unable to evaluate reasons for nonadherence or discontinuation because they are not available in claims data. Nevertheless, we did evaluate adherence in subgroups of patients without certain types of cancer or infection diagnoses that could have resulted in withholding or discontinuation of the biologic and found that it did not affect our main adherence results. Fourth, our study sample was limited to three state Medicaid programs and our results may not be representative of other states or the entire Medicaid population. Nevertheless, the CA, NY, and FL Medicaid programs do comprise a substantial proportion of the total Medicaid enrollment (32% in FY 2006) [24] . Lastly, due to delays in MAX data release, our data were limited to the periods from 1999 to 2003, the latest available data at the time of the study. It is possible that late-stage RA patients were more likely to receive biologics during that time period whereas early stage RA patients are more likely to receive biologics in current clinical practice. Our subgroup analysis in newly diagnosed RA patients indicated that adherence was slightly lower for both etanercept and infliximab and slightly higher for anakinra. Given that etanercept and infliximab are more commonly used RA biologics, this finding highlights that adherence is likely to be lower among early-stage RA patients. This may be either reflective of the disease coming under control after a few months of biologic use and hence discontinuation of the biologic or that patients with low disease severity are less likely to be adherent. Nevertheless, this suggests that our findings in the overall sample provide an upper bound on the estimates of adherence among Medicaid patients in today's clinical practice.
In summary, this study highlights the poor adherence to and premature discontinuation without concurrent switching of infliximab, etanercept, and anakinra among patients newly initiating these agents that should raise concern for clinicians and payers alike. Future studies should evaluate the clinical and economic consequences associated with such suboptimal patterns of use of these highly effective but expensive biologic agents.
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